Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Martin Hutchings

Martin Hutchings

MD, PhD
Copenhagen University Hospital

Academic History

Martin Hutchings, MD, PhD, obtained his medical degree and PhD from the University of Copenhagen, Copenhagen, Denmark. Dr Hutchings is the head of service for Hodgkin lymphoma, mantle cell lymphoma, and Castleman’s disease and a staff specialist in the Department of Hematology at the Finsen Centre Laboratory of the Copenhagen University Hospital, Copenhagen, Denmark. 

Speaking on bispecific antibody treatment in patients with lymphoma

As well as treating patients with lymphoma, Dr Hutchings is a national principal investigator or sub-investigator in a variety of clinical trials investigating novel agents in solid and liquid malignancies. He has held the position of chairman of the Scientific Steering Committee for the EORTC Lymphoma Group since 2013 and co-authored both the international response criteria and guidelines for the use of imaging in lymphoma and the European Society of Medical Oncology (ESMO) guidelines for Hodgkin lymphoma and ’ultra high-risk’ lymphomas.

The use of bispecific antibodies and other immunotherapeutics in early lines of treatment for NHL 18:55
The use of bispecific antibodies and other immunotherapeutics in early lines of treatment for NHL
Elizabeth Budde et al. • 28 Sep 2025
The BP41072 trial: glofitamab plus englumafusp alfa in patients with R/R B-NHL 3:17
The BP41072 trial: glofitamab plus englumafusp alfa in patients with R/R B-NHL
Martin Hutchings • 7 Dec 2024
Updates from the Phase II trials of glofitamab and epcoritamab for R/R LBCL 1:49
Updates from the Phase II trials of glofitamab and epcoritamab for R/R LBCL
Martin Hutchings • 7 Dec 2024
Extended follow-up of glofitamab with polatuzumab in heavily pre-treated R/R LBCL, including HGBCL 2:02
Extended follow-up of glofitamab with polatuzumab in heavily pre-treated R/R LBCL, including HGBCL
Martin Hutchings • 7 Dec 2024
Bispecific antibodies in NHL: comparisons with CAR-T, managing toxicities, & combination approaches
Krish Patel et al. • 10 Oct 2024
Exciting advancements in NHL from EHA 2024 0:43
Exciting advancements in NHL from EHA 2024
Martin Hutchings • 15 Jun 2024
An update on the COBRA trial: PET-response adapted treatment with brentuximab vedotin for HL 2:39
An update on the COBRA trial: PET-response adapted treatment with brentuximab vedotin for HL
Martin Hutchings • 15 Jun 2024
Should bispecifics or CAR-T be given first in R/R FL? 1:50
Should bispecifics or CAR-T be given first in R/R FL?
Martin Hutchings • 15 Jun 2024
Updated results of glofitamab plus polatuzumab vedotin combination therapy in DLBCL, including HGBCL 2:54
Updated results of glofitamab plus polatuzumab vedotin combination therapy in DLBCL, including HGBCL
Martin Hutchings • 10 Dec 2023
Extended follow-up of glofitamab monotherapy in R/R LBCL: durability of CR and likelihood of CRS 3:58
Extended follow-up of glofitamab monotherapy in R/R LBCL: durability of CR and likelihood of CRS
Martin Hutchings • 10 Dec 2023
Bispecific antibodies in NHL
Krish Patel et al. • 17 Oct 2023
Assessing the dynamics of CD8-expressing cells in patients with R/R LBCL treated with glofitamab 1:32
Assessing the dynamics of CD8-expressing cells in patients with R/R LBCL treated with glofitamab
Martin Hutchings • 11 Dec 2022
Evaluating RO7443904 in combination with glofitamab in patients with R/R NHL 1:08
Evaluating RO7443904 in combination with glofitamab in patients with R/R NHL
Martin Hutchings • 11 Dec 2022
Insights into Phase I/II study assessing fixed-duration glofitamab treatment for R/R LBCL 2:43
Insights into Phase I/II study assessing fixed-duration glofitamab treatment for R/R LBCL
Martin Hutchings • 11 Dec 2022
Phase I study of costimulatory bispecific antibody RO7227166 combined with glofitamab in R/R B-NHL 1:46
Phase I study of costimulatory bispecific antibody RO7227166 combined with glofitamab in R/R B-NHL
Martin Hutchings • 11 Dec 2022
Glofitamab and polatuzumab vedotin in DLBCL 5:46
Glofitamab and polatuzumab vedotin in DLBCL
Martin Hutchings • 12 Dec 2021
The content of VJHemOnc is intended for healthcare professionals